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Aim: To compare radiotherapy plans made according to CT and PET/CT and to investigate
the  impact of changes in target volumes on tumour control probability (TCP), normal tissue
complication probability (NTCP) and the impact of PET/CT on the staging and treatment
strategy.
Background: Contemporary studies have proven that PET/CT attains higher sensitivity and
speciﬁcity in the diagnosis of lung cancer and also leads to higher accuracy than CT alone
in  the process of target volume delineation in NSCLC.
Materials and methods: Between October 2009 and March 2012, 31 patients with locally
advanced NSCLC, who had been referred to radical radiotherapy were involved in our study.
They all underwent planning PET/CT examination. Then we carried out two separate delin-
eations of target volumes and two radiotherapy plans and we  compared the following
parameters of those plans: staging, treatment purpose, the size of GTV and PTV and theexposure of organs at risk (OAR). TCP and NTCP were also compared.
Results: PET/CT information led to a signiﬁcant decrease in the sizes of target volumes, which
had  the impact on the radiation exposure of OARs. The reduction of target volume sizes wasnot reﬂected in the signiﬁcant increase of the TCP value. We  found that there is a very strong
direct linear relationship between all evaluated dosimetric parameters and NTCP values of
all  evaluated OARs.
∗ Corresponding author. Tel.: +420 377105605.
E-mail address: vojtisekr@fnplzen.cz (R. Vojtísˇek).
1507-1367/$ – see front matter © 2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
http://dx.doi.org/10.1016/j.rpor.2013.09.006
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Conclusions: Our study found that the use of planning PET/CT in the radiotherapy planning
of  NSCLC has a crucial impact on the precise determination of target volumes, more  precise
staging of the disease and thus also on possible changes of treatment strategy.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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Table 1 – Patients and disease characteristics.
All patients (n = 31)
Sex
Male 26 (83.9%)
Female 5 (16.1%)
Age at the time of diagnosis (median, range) 68 (56–80)
Side
Right 21 (67.7%)
Left 10 (32.3%)
Histology
Squamous cell carcinoma 24 (77.4%)
Adenocarcinoma 7 (22.6%)
Dose delivered (Gy; median; range) 66 (40.5–80)
Stage according to CT
IA 0
IB 2 (6.4%)
IIA 1 (3.2%)
IIB 0
IIIA 18 (58.1%)
IIIB 6 (19.4%)
IV 4 (12.9%)
Stage according to PET/CT
IA 0
IB 2 (6.4%)
IIA 0
IIB 3 (9.7%)
IIIA 17 (54.8%)
IIIB 6 (19.4%)
IV 3 (9.7%)
Radiotherapy purpose according to CT
Radical 27 (87.1%)
Palliative 4 (12.9%).  Background
n the current practice of radiotherapy planning and target vol-
me  determination in patients suffering from non-small cell
ung cancer (NSCLC), a contrast-enhanced CT is usually used.
nfortunately, there are several clinical situations where we
ften encounter difﬁculties in contouring target volumes, as
n the cases of tumour-related atelectasis, spiculated lesions
nd lesions close to the dystelectatic changes. Also, there are
o adequate size-based criteria for nodal involvement assess-
ent for these patients.1
Contemporary studies have proven that hybrid PET/CT
xamination has higher sensitivity and speciﬁcity in the diag-
osis of lung cancer2 and also leads to higher accuracy in the
rocess of target volume delineation in NSCLC.
Although the prognosis of patients with NSCLC in stage III
as become better in recent years, it is very difﬁcult to improve
he local control of the disease using conventional fractiona-
ion schedules and conventional doses (60 Gy).3 This seems
o be feasible by using accelerated hyperfractionated radio-
herapy (HART,4 CHARTWEL5,6), which increases toxicity, or by
ncreasing the dose delivered to the target volumes, but it has
een proven that the tolerance of surrounding organs at risk
nhibits this effort.7 On the other hand, reduction of the tar-
et volumes should lead to the possibility of delivering higher
oses and thus to the increasing of tumour control probability
TCP) with acceptable normal tissue complication probability
NTCP). Nowadays, it seems that the way to reduce target vol-
mes is to use the most precise imaging modality possible,
ptimally PET/CT.
Therefore, we  proposed a representative study comparing
adiotherapy plans made according to CT and PET/CT exami-
ations in the same patient. For these comparative purposes
e used different dose-volume parameters and sizes of tar-
et volumes. Furthermore, we  investigated the impact of the
hanges in target volume sizes on TCP and NCTP and the
mpact of combined PET/CT examination on the staging of the
isease and treatment strategy. According to our best knowl-
dge, there has been no study published investigating the
elationship between target volume changes that developed
ccording to the use of PET/CT and NTCP values for all relevant
rgans at risk in the chest.
.  Patients  and  methods.1.  Patients
etween October 2009 and March 2012, 31 patients (26 men
nd 5 women, with a median age of 68, see details in
able 1) suffering from histologically proven, inoperable,Radiotherapy purpose according to PET/CT
Radical 27 (87.1%)
Palliative 4 (12.9%)
locally advanced NSCLC referred for radical radiotherapy –
either as a single method or in combination with chemother-
apy, sequential or concomitant – took part in our study.
2.2.  Radiotherapy  simulation  and  image  acquisition
All patients underwent initial preparation at the Department
of Oncology and Radiotherapy, University Hospital in Pilsen,
according to our institutional standards, i.e. the choice of
proper positioning and immobilization devices (we  normally
use WingBoardR, MED-TEC, for immobilization of the upper
arms when patients are in the supine position with both arms
above the head), determination of the reference plane on X-
ray simulator and drawing of the projection points of the
simulated isocentre on the patient‘s skin. Planning PET/CT
examination was carried out at the Department of Imaging
d rad184  reports of practical oncology an
Methods at the same hospital and in the same way as rou-
tine diagnostic examinations with the exception that patients
were positioned in radiotherapy positions with dedicated
immobilization devices. The concavity of the examination
table was compensated for with a radiolucent hand-made
board. Patients were placed into the required position with
the help of a laser positioning system, the projection points
on the skin were marked with radiopaque marks.
PET scans were performed 60 min  after the intravenous
administration of 18FDG (2-[18F]ﬂuor-2-deoxy-d-glucose) with
a radioactivity level of about 400 MBq. 1000 ml  of a 2.5% solu-
tion of mannitol was used as bowel preparation. CT scans were
performed on a Biograph HiRez/16 slice (Siemens, Forcheim,
Germany) after intravenous administration of 100 ml  of a non-
ionic iodine contrast agent between the base of the skull and
the inguinal region. CT scans were performed during inhala-
tion, during PET acquisition the patient was instructed to
breathe slowly and shallowly. CT and PET scans were then
exported to our treatment planning system PlanW 2000.
In this treatment planning system PET units are trans-
ferred to grey values (GVal) following the next formula (Disp-
Window = user-adjustable display window of PET units matrix;
typical example: wide display window has DispWindow.
LowLevel = 0 and DispWindow.HighLevel = 32,600): if PET
units ≤ DispWindow.LowLevel, then GVal = 0; if PET
units ≥ DispWindow.HighLevel, then GVal = 255; and if
GVal = round (255 × (PET number − DispWindow.LowLevel)/
(DispWindow.HighLevel − DispWindow.LowLevel)). Grey val-
ues (GVal) are transferred to red, green and blue (R, G, B)
scheme following the next formula: if GVal ≥ 128, then TPS
use R = 255, G = 2 × (GVal − 128) and B = 0; if GVal ≤ 128, then
TPS use R = min  (2 × GVal, 255), G = 0 and B = 0. Typical exam-
ple: for wide display window (DispWindow.LowLevel = 0 and
DispWindow.HighLevel = 32,600) the bright red colours start
from PET units about 10,000 and bright yellow colours start
from PET units about 23,000.
2.3.  Radiotherapy  planning
Contouring of all plans was carried out in two separate ses-
sions by the same radiation oncologist (R.V.). First, we used
only CT data for contouring (as we did not pay attention to
results from PET scans) and we  delineated target volumes GTV
(Gross Tumour Volume), CTV (Clinical Target Volume), PTV
(Planning Target Volume) and organs at risk according to the
ICRU Report 508 and 62 recommendations.9 Delineation was
carried out using the lung (GTV-T) and the mediastinal win-
dows (GTV-N). Subsequently, we merged the copied CT scans
with PET scans and carried out a new delineation of target
volumes according to the same recommendations. No mathe-
matical algorithm for automatic contouring of GTV was used
nor any threshold for SUV (standardized uptake value). It was
an entirely subjective contouring based on detailed descrip-
tions of pathological ﬁndings. We  consulted a radiologist in
case of doubts and used all accessible clinical information,
as per the latest recommendations.10 The margin between
GTV and CTV was 5 mm and the margin between CTV and
PTV was 10–15 mm depending on the breathing excursions
found during the ﬁrst X-ray simulation. Until November 2010,
we were standardly using the “shrinking-ﬁeld” technique withiotherapy 1 9 ( 2 0 1 4 ) 182–190
elective nodal irradiation (ipsilateral hilum and mediastinum
or both hilar regions and mediastinum). In December 2010, we
modiﬁed our own standard treatment protocol with respect
to the results of numerous clinical studies11–14 and the EORTC
recommendations.15,16 We  also did not include elective nodal
regions into target volumes anymore, but only involved nodal
stations.
We also contoured all at-risk organs in the thorax accord-
ing to our institutional protocol – the lungs (the volume of both
lungs minus  PTV), the oesophagus (from just below the larynx
to the gastroesophageal junction), the spinal cord (deﬁned by
the inner margin of the bony spinal canal) and the heart (the
cranial extent should include the infundibulum of the right
ventricle and the apex of both atria while excluding the great
vessels as much as possible, and the caudal border deﬁned
by the lowest part of the ventricle’ inferior wall that is distin-
guishable from the liver).
Subsequently, two plans were made with the same pre-
scribed dose in the ICRU reference point, which differed from
case to case according to the clinical situation and the rela-
tionship with the chemotherapy administration, and with the
same dose-volume constraints of organs at risk. 30 patients
were treated with 3D-CRT (3D conformal radiotherapy) and
only 1 patient with IMRT (intensity modulated radiotherapy).
Both plans had their own dose-volume histograms for target
volumes and for organs at risk. These plans were mostly not
identical in terms of ﬁelds arrangement, they were different,
depending on the size and shape of the PTV. Eventually, we
used a radiobiological modelling programme (BioGray v. 1.5)
to obtain the parameters such as TCP (tumour control proba-
bility) and NTCP (normal tissue complication probability).
2.4.  Dose  constraints,  TCP,  NTCP
We use dose constraints in our department for organs
at risk as follows: the lungs V20 < 35%, MLD (mean lung
dose) < 20 Gy, the spinal cord Dmax < 50 Gy, the heart V33 < 60%,
Dmean < 46 Gy and the oesophagus V50 < 30%, V55 < 28%,
V35 < 65%, Dmax < 70 Gy.16,17
TCP (tumour control probability) and NTCP (normal tissue
complication probability) reﬂect the effectiveness or toxicity
of radiotherapy schemes. Generally, the TCP value should be
as high as possible (100% being unattainable). The NTCP shows
the probability of occurrence of early or late toxicity in organs
(tissue) as a result of radiotherapy. Especially the manifesta-
tions of late toxicity can severely decrease the quality of life
or endanger the viable tissues (paralysis, blinding, etc.).
In an effort to obtain these parameters, we used the BioGray
v. 1.5 programme, which is a comprehensive programme dedi-
cated to modelling and predicting radiobiological late or early
effects in radiotherapy as well as the probability of tumour
control. The programme is based on a linear-quadratic model
(LQM) using the concept of a biological effective dose (BED)
created by Barendsen18 and the 4-component Lyman model
for calculating NTCP and TCP. The programme works using
a method of simultaneous simulation of effects on selected
tissues. It calculates the radiobiological status after every frac-
tion of therapy for each tissue, namely the cumulative applied
dose, BED, TCP and NTCP. The results of these calculations
may be displayed either as a function of time or applied
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hysical (cumulative) dose.19 The programme contains a
ibrary of predeﬁned items representing critical structures and
umour types with entered parameters that correspond to
 radiobiological model and its characteristics. According to
VH of a structure (and target volume), the maximum dose
nd percentage partial volume is determined and these values
re used to adjust the actual structure irradiation.
.5.  Compared  parameters
e  compared the following parameters: staging, aim of treat-
ent, the size of GTV and PTV (or PTV reduced in situations
hen patients were treated with the “shrinking-ﬁeld” tech-
ique in two phases), the exposure of organs at risk – the lungs
13, V20, MLD; the spinal cord Dmax; the heart V33, Dmean and
he oesophagus V50, TCP and NTCP of all organs at risk.
.6.  Ethics
s this was a planning/modelling study, patients were diag-
osed and treated according to standard guidelines at our
nstitute.
.7.  Statistics
he following methods were used for statistical analyses of
he data ﬁle:
Frequency tables of absolute and relative frequencies and
he contingency tables of simultaneous absolute and relative
requencies.
Descriptive statistics of observed variables, i.e. the mean,
he median, the range and the standard deviation.
Paired tests comparing the mean values or the medians of
wo variables surveyed on the same object, either the paired
-test (in case the variables are normally distributed) or the
aired Wilcoxon test (in case the variables are not normally
istributed).
Tests of the independence of two variables: the asymptotic
2-test of the independence for the nominal variables; a test
f the serial independence with the use of Spearman corre-
ation coefﬁcient for the ordinal variables or the continuous
ariables that are not bivariate normally distributed; a test of
he stochastic independence with the use of correlation coefﬁ-
ient for the continuous variables, that are bivariate normally
istributed.
For descriptive statistics, the means are given ± standard
eviation (SD) or the medians are given ± interquartile range
IQR).
.  Results
.1.  Change  of  staging  and  its  inﬂuence  on  the
reatment  strategy
he ﬁndings obtained from PET/CT examination led in 9
atients (29%) to upstaging of the disease evaluated according
o separate CT examination, in 10 patients (32.3%) to down-
taging and in 12 patients (38.7%) no change was observed
etween the stages evaluated according to CT and PET/CT.therapy 1 9 ( 2 0 1 4 ) 182–190 185
When the CT ﬁndings underestimated the extent of the
disease, new ﬁndings (metastatic disease) led to changes in
treatment strategy in 3 patients (9.7%), namely to palliative
radiotherapy (2 patients, 6.5%) and palliative chemotherapy (1
patient, 3.2%). When the CT ﬁndings overvaluated the extent
of the disease, radical treatment was started in 3 patients
(9.7%), although it would be not indicated based on a CT scan
alone.
Change in the sizes of target volumes GTV (gross tumour
volume) and PTV (planning target volume).
Incorporating PET/CT scan information in target-volume
contouring led to a signiﬁcant decrease of the sizes of
target volumes unlike the contouring using separate CT
scan information: the median GTVCT = 61 cm3 ± 92.6 (range
19.4–431.7 cm3), median GTVPET/CT = 52.5 cm3 ± 70.3 (range
15.7–399 cm3); p = 0.001. Median PTVCT = 320 cm3 ± 212.4 (range
151.2–1204 cm3). Median PTVPET/CT = 262.7 cm3 ± 169.5 (range
107.9–1147 cm3); p < 0.001 (see Table 2).
3.2.  Radiation  exposure  of  healthy  lung  tissue  and
NTCP
Comparing PET/CT planning with CT planning only, we  found
that radiation exposure of healthy lung tissue decreased
insigniﬁcantly: the mean V13 from 39.8% ± 20.6 (range 9–81%)
to 38.7% ± 20.9 (range 8–82%), p = 0.176; the mean V20 from
30.4% ± 16.4 (range 7–73%) to 30.2% ± 17.1 (range 6–73%),
p = 0.428; and the mean of mean lung dose (MLD) from
16.2 Gy ± 6.8 (range 4–29.6 Gy) to 16 Gy ± 7.0 (range 3.6–29.8 Gy),
p = 0.328.
Identiﬁed NTCP values did not differ between dif-
ferent means of radiotherapy planning: the median
NTCPCT = 14.8% ± 16.6 (range 4–50%) and the median
NTCPPET/CT = 13.7% ± 19.4 (range 4–54%), p = 0.355.
3.3.  Radiation  exposure  of  the  oesophagus  and  NTCP
The use of PET/CT led to a signiﬁcant decrease in radiation
exposure of the oesophagus analyzed according to the value
V50: the median decreased from 16% ± 42 (range 0–72%) to
11% ± 37 (range 0–70%); p = 0.0033.
The median of NTCP has decreased from 30.8% ± 39.8
(range 0–76%) to 25.7% ± 45.2 (range 0–75%); p < 0.001.
3.4.  Radiation  exposure  of  the  spinal  cord  and  NTCP
Also, radiation exposure of the spinal cord with the use
of PET/CT planning was lower: the median Dmax decreased
from 43.6 Gy ± 10.5 (range 14.9–51.9 Gy) to 40 Gy ± 17.9 (range
3.2–49.9 Gy); p = 0.0065.
The change of NTCP values was not statistically evalu-
able, because we had a very low number of nonzero
values.
3.5.  Radiation  exposure  of  the  heart  and  NTCPThe same results were found in evaluation of radiation
exposure of the heart, incorporating the PET/CT to the
planning led to a decrease in all analyzed dosimetric param-
eters: the median V33 decreased from 18% ± 22.5 (range
186  reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 182–190
Table 2 – Changes of target volumes sizes and TCP with the use of PET/CT.
Target volume The size of target volume (median, IQR, range) TCP (median, IQR, range), in %
CT PET/CT p-Value CT PET/CT p-Value
GTV (cm3) 61 ± 92.6
(19.4–431.7)
52.5  ± 70.3
(15.7–399)
0.001 68.1 ± 34.8(4.4–88) 69.1 ± 32.5
(4.2–88)
0.857
PTV (cm3) 320 ± 212.4
(151.2–1204)
262.7 ± 169.5
(107.9–1147)
p  < 0.001
Abbreviations:  GTV, gross tumour volume; PTV, planning target volume; IQR, interquartile range; TCP, tumour control probability.
Table 3 – Dosimetric parameters of organs at risk and subsequent NTCP values of all eligible patients (n = 29).
Parameter Radiation exposure (median,a IQR,a range) NTCP (median,a IQR,a range)
CT PET/CT p-Value CT PET/CT p-Value
Lung (%) 14.8 ± 16.67
(4–50)
13.7 ± 19.46
(4–54)
0.355
V13 (%) 39.8 ± 20.6
(9–81)
38.7 ± 20.9
(8–82)
0.176
V20 (%) 30.4 ± 16.4
(7–73)
30.2 ± 17.1
(6–73)
0.428
Mean lung dose (Gy) 16.2 ± 6.8
(4–29.6)
16 ± 7
(3.6–29.8)
0.328
Oesophagus (%) 30.8 ± 39.8
(0–76)
25.7 ± 45.2
(0–75)
<0.001
V50 (%) 16 ± 42
(0–72)
11  ± 37
(0–70)
0.0033
Spinal cord (%) 0  ± 0.5
(0–2)
0  ± 0.5
(0–2)
NE
Maximal dose 43.6 ± 10.5
(14.9–51.9)
40 ± 17.9
(3.2–49.9)
0.0065
Heart (%) 0.5 ± 5 (0–44) 0 ± 4.8
(0–44)
0.0116
V33 (%) 18 ± 22.5
(0–47)
16  ± 24
(0–51)
0.007
Mean heart dose (Gy) 17.2 ± 17.5
(1.6–31.8)
14.4 ± 17.8
(0–31.8)
0.0017
Abbreviations:  Vx, volume of organ receiving at least x Gy; IQR, interquartile range; NTCP, normal tissue complication probability; SD, standard
deviation; NE, not evaluable.
a Except lung parameters, those are expressed as the mean and SD.
0–47%) to 16% ± 24 (range 0–51%), p = 0.007; and the median
Dmean from 17.2 Gy ± 17.5 (range 1.6–31.8 Gy) to 14.4 Gy ± 17.8
(range 0–31.8 Gy), p = 0.0017.The median of NTCP decreased
from 0.5% ± 0.5 (range 0–44%) to 0% ± 4.8 (range 0 44);
p = 0.0116.
3.6.  Inﬂuence  of  size  change  in  target  volumes  on  TCP
Although a signiﬁcant reduction of the target-volume (GTV
and PTV) sizes was found, it was not reﬂected in the signiﬁcant
increase of the TCP value: the median TCPCT was 68.1% ± 34.8
(range 4.4–88%) and the median TCPPET/CT 69.1% ± 32.5 (range
4.2–88%); p = 0.857 (see Table 2).The only ﬁndings made only showed a very weak, indirect,
ordinal relationship between the size of GTV and the TCP value
(Spearman’ rank correlation coefﬁcient was −0.167 and −0.282
with the use of CT and PET/CT, respectively).3.7.  Inﬂuence  of  size  change  of  radiation  exposed
organs  at  risk  on  NTCP
Our results do conclude that there is a very strong direct linear
relationship between all evaluated dosimetric parameters and
NTCP values of all evaluated organs at risk (see Table 3).
4.  Discussion
It has already been proven that a PET/CT imaging method is
more  precise than a CT scan alone in the assessment of lymph
nodes status in lung cancer. Even PET/CT scanning is not the
most precise method in predicting nodal involvement, as there
is no doubt that currently the most precise method is a biopsy
of suspected nodes. It has higher sensitivity and speciﬁcity as
it has been proven in studies of Vanuytsel et al.20 and Faria
et al.21
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PET/CT examination also helps to determine the primary
umour close to the atelectatic lung area. Doses between 60
nd 70 Gy, which are commonly used in the treatment of
ocoregionally advanced lung cancer, are associated with fre-
uent incidence of relapse and very dismal survival rates,22
ecause it has been conclusively proven that there is a clear
ssociation between total dose, local control and overall sur-
ival of patients treated for NSCLC.23,24 Currently, there is an
ffort to irradiate the smallest target volume with the highest
ose possible while sparing the surrounding at-risk organs to
he highest degree. To reach this aim, the latest imaging meth-
ds are used because they are able to precisely determine the
arget volume. This is especially true of PET/CT examination.
During contouring of GTV neither mathematical algo-
ithm nor threshold for SUV (standardized uptake value) was
sed, it was entirely subjective contouring based on detailed
escriptions of pathological ﬁnding and all accessible clinical
nformation. The resolution of PET is low, average 4.5 mm,  so
he margins of the displayed tumour are somewhat blurred
nd human eye is not easily able to distinguish the borders of
he target volume. This is also inﬂuenced by the software, the
ontrast between the tumour and the background and other
rtefacts.25 There are several possibilities and ways how to
eﬁne the borders of GTV on PET scans described in the liter-
ture. The ﬁrst ever method described is the utilization of all
ccessible clinical information, knowledge and experience of
 planning radiation oncologist, the method of visual assess-
ent. It relies on a visual assessment of the PET image  to
dentify and select areas of pathological uptake. These areas
re then contoured by CT to take advantage of the greater
patial resolution of CT, which allows for a clear deﬁnition
f the tumour border (unlike PET).26 The second way, which
as explored, is the use of mathematical automatic or semi-
utomatic models for the determining of the borders. For
his purpose, some threshold cut-off values are used, either
he percentage of the maximal SUV (40%,27–29 42%30,31 and
0%25,32,33) or the absolute value of SUV (usually SUV 2,534).
btaining “the magical line” between malignant and normal
issue is as yet impossible.35 According to the latest recom-
endations, the ﬁrst method (visual assessment) should be
sed for contouring.10
In our study we  found out that in radiotherapy planning
here is a signiﬁcant decrease of the target volumes with the
se of PET/CT, which is mainly caused by omitting the unin-
olved lymph node groups (better deﬁned by PET/CT) and by
ore accurate deﬁnition of the primary tumour (differentia-
ion from dystelectatic changes or atelectasis). The changes
n target volume sizes often reﬂect the changed staging of
he disease, particularly in terms of the changed assessment
f the lymph node involvement. Changes in staging can also
ead to a change in treatment strategy,36 especially when dis-
ant metastases are found. We found that in 9 out of all 31
atients, PET/CT led to upstaging of the disease diagnosed
y CT alone and in 10 patients PET/CT led to downstaging.
f the patients upstaged by PET/CT, in 6 cases the upstaging
as caused by a change in the “N” category and in 3 patients
istant metastases were found, leading to a change of the
reatment strategy.
Our results are in accordance with published studies
elated to this topic. Erdi et al.30 published their own studytherapy 1 9 ( 2 0 1 4 ) 182–190 187
with a very modest number of 11 patients with NSCLC and they
evaluated the impact of PET/CT performed subsequently after
classical CT examination on the contouring of target volumes.
An increase in target volumes was observed in 7 patients –
especially inﬂuenced by newly diagnosed positive lymph node
groups – and a decrease was observed in 4 patients, caused by
omitting the atelectatic areas from the target volume. Brian-
zoni et al.27 evaluated 28 patients who were investigated on
an integrated PET/CT scanner. Generally, only 25 patients were
evaluated, because in the remaining 3 patients the stage was
modiﬁed and led to a change in treatment strategy. In 14 (56%)
patients the information from PET did not lead to a signiﬁcant
change in target volumes, whereas in 11 (44%) patients that
information led to a change in target volumes – in 5 of them
it was decreased (2 patients had atelectasis and in 3 patients
false positive lymph nodes on CT scan were observed) and in
6 of them increased (in 3 patients false negative lymph nodes
on CT scan were observed and 3 patients had atelectasis).
Ashamalla et al.37 compared the contouring of GTV and PTV
according to CT and PET/CT images created on an integrated
scanner in 19 patients staged as II–IIIB NSCLC. A signiﬁcant
change in the size of GTV was found in 10 (52%) patients – in
5/10 patients the volume was increased and in the same num-
ber of patients it decreased. Changes in the size of PTV were
observed in 8 (42%) patients. Bradley et al.28 compared radio-
therapy plans for 26 patients with I–III stage NSCLC. A change
in TNM classiﬁcation was observed in 8 (31%) patients. In 2
patients metastatic disease was found and, therefore, these
patients were not further enrolled in the study. In 14/24 (58%)
patients PET examination distinctly changed the sizes of tar-
get volumes. In 3 patients PET examination helped distinguish
the primary tumour from a collapsed atelectatic lung (the
decrease of the volume), unexpected nodal involvement was
detected by PET in 10 patients and in 1 patient another tumour
lesion in the same lobe was found (an increase in volume).
Change in target volume sizes leads to a change in the
irradiated volume of organs at risk. In this context, the differ-
entiation of the atelectasis from the tumour is of the greatest
importance, leading to a decrease in the probability of pneu-
monitis and oesophagitis.28,38 In our study we  observed that
the change of target volume sizes has only a slight impact
(statistically insigniﬁcant) on the radiation exposure of lung
tissue, but there is a signiﬁcant impact on the radiation expo-
sure on oesophagus, heart and spinal cord. In our case the
decrease of target volume sizes led to the decrease of dosi-
metric parameters of organs at risk, except the lung tissue.
This could be due to the fact, that in the ﬁrst half of our study
we performed the elective nodal irradiation and thus a sub-
stantial part of healthy lung tissue was exposed regardless
of the size of GTV. The decrease of dosimetric parameters
was followed by a signiﬁcant decrease of NTCP values. Sim-
ilar Australian study39 also did not reveal a signiﬁcant change
in MLD (mean lung dose) and V20 (p = 0.801 and 0.816, respec-
tively) in radiotherapy plans made on the basis of CT and
PET/CT in 10 patients with NSCLC, although in all cases a
small part of PTVPET/CT (10–40%) was outside the PTVCT; in 3
cases even the whole volume of PTVPET/CT was outside the
PTVCT (geographical miss). Five patients had atelectasis that
was clearly distinguished by PET. In other study Ceresoli et al.40
did not report signiﬁcant changes regarding the irradiated
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volumes of healthy lung tissue when PET/CT fusion was used
for target volume contouring. But they found out the change
in the maximum point dose to the spinal cord (Dmax), which
was signiﬁcantly lower in PET/CT plans. Their results are in
accordance with our ﬁndings. In their study with 21 enrolled
patients a signiﬁcant change in volume between GTVCT and
GTVPET/CT was also observed – GTVPET/CT was greater in 5
patients mainly due to the inclusion of pathological lymph
nodes; GTVPET/CT was smaller in 2 patients due to the exclu-
sion of enlarged lymph nodes and atelectatic area. In an
extensive study comparing target-volume contouring on the
basis of CT and PET/CT, Deniaud-Alexandre et al.32 reported
on the impact of changes in these volumes on the irradiation
of organs at risk. They evaluated only radiation exposure of the
lung (V20) and the heart (V36) in 92 patients. The volume of GTV
decreased by PET/CT in 21 (23%) patients, the median of the
change was 32.7% (range 2.5–143%) and in 24 (26%) patients the
volume of GTV increased, the median of the change was 18.5%
(range 1.5–77.5%). Of 81 patients receiving a total dose greater
or equal to 60 Gy, the percentage of total lung volume receiving
more  than 20 Gy (V20) increased in 15 patients (median 15.4%)
and decreased in 22 patients (median 12.5%). The percentage
of total heart volume receiving more  than 36 Gy (V36), predict-
ing cardial toxicity, increased in 8 patients (median 53.5%) and
decreased in 14 patients (median 65.5%).
When radiation exposure of organs at risk is decreased, the
dose delivered to the target volume can be escalated and thus
the probability of local control of the disease can be improved,
expressed radiobiologically in numbers as TCP. We also com-
pared TCP values of two treatment plans only according to the
change of GTV and changed stage of the disease and we found
that although signiﬁcant decrease of GTV was reached, it was
not reﬂected by increased median of TCP value. It was probably
due to the same comparing doses, unlike in the below men-
tioned studies. The decrease of GTV itself (without increasing
the delivered dose) could not lead to the increase of the TCP,
but it has to be followed by the increase in the delivered dose if
possible. Van Der Wel et al.41 tried to ﬁnd a maximum feasible
dose delivered to target volume while respecting the tolerance
doses in situations when the decreased radiation exposure of
the oesophagus and the lung were observed from PET data.
They evaluated 21 patients suffering from NSCLC with nodal
stage N2–N3 according to CT. Radiation ﬁelds were reduced in
11 patients, enlarged in 3 patients and remained unchanged in
7 patients. Delivered dose could be escalated from 56 ± 5.4 Gy
to 71 ± 13.7 Gy (p = 0.038), thereby TCP could be increased from
14.2 ± 5.6% to 22.8 ± 7.1% (p = 0.026). Dutch authors De Ruyss-
cher et al.7 approached this issue in a very similar way. They
also evaluated the change of delivered doses to organs at risk
and the inﬂuence on possible dose escalation leading conse-
quently to the increase of the TCP value. 21 patients enrolled
in their study suffered from locally or locoregionally advanced
NSCLC, all of them had radiotherapy plan made according
to CT and PET/CT. For assessment of radiation exposure of
the oesophagus and the lung they used following parame-
ters: MOD  (mean oesophageal dose), V55 and MLD and V20,
respectively. PET/CT data led to a signiﬁcant reduction of the
dosimetric parameters of both, the oesophagus and the lung.
Two-thirds of plans were changed with regard to PET data,
in 2 patients the target volume was increased, in 12 patientsiotherapy 1 9 ( 2 0 1 4 ) 182–190
decreased and remained unchanged in 7 patients. The above
mentioned ﬁndings were the background for dose escalation
modelling. Delivered dose was increased from 55.2 ± 2.0 Gy to
68.9 ± 3.3 Gy (p = 0.002) and as a consequence, the TCP value
increased from 6.3 ± 1.5% to 24.0 ± 5.6% (p = 0.01).
5.  Conclusions
We found in our study that the use of PET/CT examination in
planning of radiotherapy for non-small cell lung cancer has a
crucial impact on the precise determination of target volumes,
precise staging of the disease and thus also on possible change
of treatment strategy. If the target volume size decreases, the
dose delivered to this volume can be escalated and thus the
TCP value can increase, meaning that the probability of local
disease control can be increased while the toxicity of organs
at risk remains acceptable. The probability of developing the
toxicity of organs at risk is usually evaluated either accord-
ing to dose-volume histograms or NTCP values, expressing
the probability of damage of organs at risk. Further studies
comparing TCP and NTCP values with clinical outcomes are
warranted and we will continue our efforts in this area in our
future studies.
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